Advertisement

Acta Neuropathologica

, Volume 112, Issue 3, pp 253–260 | Cite as

Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

  • Kurt A. JellingerEmail author
  • Johannes Attems
Original Paper

Abstract

The morphological differentiation of Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB) is a matter of discussion. The objective of this study was to investigate the regional distribution of ß-amyloid (Aß) plaques, α-synuclein (AS), and pathology in both disorders. The basal ganglia from 17 age-matched patients of PDD and DLB each were immunohistochemically examined with variable degrees of associated Alzheimer pathology using antibodies to Aß, AS, and tau. DLB brains showed a significantly higher burden of (diffuse) amyloid plaques in the putamen and caudate nucleus and slightly more severe tau pathology than PDD brains despite similar neuritic Braak stages. Phases of Aß development in DLB brains often, but inconsistently, correlated with both neuritic Braak stages and severity of striatal Aß load, while these correlations were almost never seen in PDD cases with Alzheimer lesions. They also revealed a higher burden of AS-lesions (both Lewy neurites and Lewy bodies) than PDD cases that commonly had a paucity of all three types of lesion. The globus pallidus was virtually spared in both phenotypes. Differences in AS and Aß pathologies and much less of tau lesions in the striatum support a morphologic distinction between PDD and DLB, which may be of pathophysiologic importance, but the causes of these differences are unclear.

Keywords

Parkinson disease with dementia Dementia with Lewy bodies Striatal α-synuclein Aß plaques 

Notes

Acknowledgments

The study was supported by the Society for Support of Experimental Neurology, Vienna, Austria. The authors thank Mrs. V. Rappelsberger for excellent laboratory work, and Mr. E. Mitter-Ferstl, Ph.D., for secretarial and computer work.

References:

  1. 1.
    Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17:137–145PubMedCrossRefGoogle Scholar
  2. 2.
    Aarsland D, Perry R, Brown A, Larsen JP, Ballard C (2005) Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 58:773–776PubMedCrossRefGoogle Scholar
  3. 3.
    Allsop D, Haga SI, Haga C, Ikeda SI, Mann DM, Ishii T (1989) Early senile plaques in Down’s syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol 15:531–542PubMedCrossRefGoogle Scholar
  4. 4.
    Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112PubMedCrossRefGoogle Scholar
  5. 5.
    Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRefGoogle Scholar
  6. 6.
    Braak H, Braak E (1990) Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215–224PubMedCrossRefGoogle Scholar
  7. 7.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Berl 82:239–259PubMedCrossRefGoogle Scholar
  8. 8.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  9. 9.
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMedGoogle Scholar
  10. 10.
    Brilliant MJ, Elble RJ, Ghobrial M, Struble RG (1997) The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer’s disease. Neuropathol Appl Neurobiol 23:322–325PubMedCrossRefGoogle Scholar
  11. 11.
    Brown DF, Dababo MA, Bigio EH, Risser RC, Eagan KP, Hladik CL, White CL 3rd (1998) Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 57:39–46PubMedCrossRefGoogle Scholar
  12. 12.
    Bugiani O, Giaccone G, Frangione B, Ghetti B, Tagliavini F (1989) Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neurosci Lett 103:263–268PubMedCrossRefGoogle Scholar
  13. 13.
    Cataldo AM, Barnett JL, Mann DM, Nixon RA (1996) Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer’s disease and Down’s syndrome. J Neuropathol Exp Neurol 55:704–715PubMedCrossRefGoogle Scholar
  14. 14.
    Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O’Brien JT (2005) Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 32:1176–1185PubMedCrossRefGoogle Scholar
  15. 15.
    Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O’Brien JT (2003) Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology 61:1191–1195PubMedGoogle Scholar
  16. 16.
    Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210PubMedCrossRefGoogle Scholar
  17. 17.
    Duyckaerts C (2002) Is Parkinson’s disease with dementia and dementia with Lewy body the same disease? Mov Disord 17(Suppl 5):S9Google Scholar
  18. 18.
    Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedCrossRefGoogle Scholar
  19. 19.
    Gearing M, Wilson RW, Unger ER, Shelton ER, Chan HW, Masters CL, Beyreuther K, Mirra SS (1993) Amyloid precursor protein (APP) in the striatum in Alzheimer’s disease: an immunohistochemical study. J Neuropathol Exp Neurol 52:22–30PubMedCrossRefGoogle Scholar
  20. 20.
    Gearing M, Levey AI, Mirra SS (1997) Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers. J Neuropathol Exp Neurol 56:1363–1370PubMedCrossRefGoogle Scholar
  21. 21.
    Geser F, Wenning GK, Poewe W, McKeith I (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20(Suppl 12):S11–S20PubMedCrossRefGoogle Scholar
  22. 22.
    Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K (2004) Striatal monoamine terminals in Lewy body dementia and Alzheimer’s disease. Ann Neurol 55:774–780PubMedCrossRefGoogle Scholar
  23. 23.
    Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M et al (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMedGoogle Scholar
  24. 24.
    Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMedGoogle Scholar
  25. 25.
    Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097PubMedCrossRefGoogle Scholar
  26. 26.
    Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol Berl 105:265–270PubMedGoogle Scholar
  27. 27.
    Iseki E (2004) Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology 24:72–78PubMedCrossRefGoogle Scholar
  28. 28.
    Ito H, Kusaka H, Matsumoto S, Imai T (1996) Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 47:1291–1299PubMedGoogle Scholar
  29. 29.
    Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53PubMedCrossRefGoogle Scholar
  30. 30.
    Jellinger KA, Seppi K, Wenning GK (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol Berl 106:188–189PubMedCrossRefGoogle Scholar
  31. 31.
    Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:219–235CrossRefGoogle Scholar
  32. 32.
    Jellinger KA (2006) Neuropathology of dementia in Parkinson’s disease. Ann Neurol 59:727PubMedCrossRefGoogle Scholar
  33. 33.
    Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 135:309–319PubMedGoogle Scholar
  34. 34.
    Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol Berl 106:83–88PubMedGoogle Scholar
  35. 35.
    Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM (2005) Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64:2069–2073PubMedCrossRefGoogle Scholar
  36. 36.
    Lach B, Grimes D, Benoit B, Minkiewicz-Janda A (1992) Caudate nucleus pathology in Parkinson’s disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol Berl 83:352–360PubMedCrossRefGoogle Scholar
  37. 37.
    Lees AJ (2002) Parkinson’s disease with dementia (PDD) is the same clinicopathological entity as dementia with Lewy bodies (DLB) (abstr). Mov Disord 17(Suppl 5):S9Google Scholar
  38. 38.
    Liang T, Noorigian JV, Duda JE (2006) Does striatal pathology distinguish DLB from PDD? Mov Disord 21(Suppl 13):S69–S70Google Scholar
  39. 39.
    Marui W, Iseki E, Kato M, Akatsu H, Kosaka K (2004) Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease. Acta Neuropathol 108:121–128PubMedCrossRefGoogle Scholar
  40. 40.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  41. 41.
    McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on dementia with Lewy bodies. Neurology 53:902–905PubMedGoogle Scholar
  42. 42.
    McKeith IG, Mosimann UP (2004) Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S15–18PubMedCrossRefGoogle Scholar
  43. 43.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  44. 44.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  45. 45.
    Nakabayashi J, Yoshimura M, Morishima-Kawashima M, Funato H, Miyakawa T, Yamazaki T, Ihara Y (1998) Amyloid beta-protein (A beta) accumulation in the putamen and mammillary body during aging and in Alzheimer disease. J Neuropathol Exp Neurol 57:343–352PubMedCrossRefGoogle Scholar
  46. 46.
    Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y (2004) Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 19:60–67PubMedCrossRefGoogle Scholar
  47. 47.
    O’Brien J, Ames D, McKeith I, Chiu E (eds) (2006) Dementia with Lewy bodies and Parkinson’s disease dementia. Taylor & Francis, LondonGoogle Scholar
  48. 48.
    Pappolla MA, Omar RA, Vinters HV (1991) Image analysis microspectroscopy shows that neurons participate in the genesis of a subset of early primitive (diffuse) senile plaques. Am J Pathol 139:599–607PubMedGoogle Scholar
  49. 49.
    Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I (2005) Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25:304–314PubMedCrossRefGoogle Scholar
  50. 50.
    Perneczky R, Mosch D, Neumann M, Kretzschmar H, Muller U, Busch R, Forstl H, Kurz A (2005) The Alzheimer variant of Lewy body disease: a pathologically confirmed case-control study. Dement Geriatr Cogn Disord 20:89–94PubMedCrossRefGoogle Scholar
  51. 51.
    Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) A beta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192PubMedCrossRefGoogle Scholar
  52. 52.
    Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW (2006) Striatal dopaminergic neurons are lost with Parkinson’s disease progression. Mov Disord (submitted)Google Scholar
  53. 53.
    Probst A, Langui D, Ipsen S, Robakis N, Ulrich J (1991) Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol Berl 83:21–29PubMedCrossRefGoogle Scholar
  54. 54.
    Richard IH, Papka M, Rubio A, Kurlan R (2002) Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17:1161–1165PubMedCrossRefGoogle Scholar
  55. 55.
    Rudelli RD, Ambler MW, Wisniewski HM (1984) Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol Berl 64:273–281PubMedCrossRefGoogle Scholar
  56. 56.
    Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMedGoogle Scholar
  57. 57.
    Suzuki M, Desmond TJ, Albin RL, Frey KA (2002) Striatal monoaminergic terminals in Lewy body and Alzheimer’s dementias. Ann Neurol 51:767–771PubMedCrossRefGoogle Scholar
  58. 58.
    Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733–748PubMedGoogle Scholar
  59. 59.
    Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain 129:729–735PubMedCrossRefGoogle Scholar
  60. 60.
    Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47–S51PubMedCrossRefGoogle Scholar
  61. 61.
    Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62:1568–1572PubMedGoogle Scholar
  62. 62.
    Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362PubMedCrossRefGoogle Scholar
  63. 63.
    Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS (1999) Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord 13:226–231PubMedCrossRefGoogle Scholar
  64. 64.
    Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545–547PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Institute of Clinical NeurobiologyViennaAustria
  2. 2.Department of PathologyOtto Wagner HospitalViennaAustria

Personalised recommendations